Cargando…

Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity

We investigated the long-term visual and anatomical outcomes of aflibercept monotherapy for exudative age-related macular degeneration (AMD) with good baseline best-corrected visual acuity (BCVA). A medical chart review was performed for 40 consecutive patients with baseline decimal BCVA ≥ 0.6 secon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kikushima, Wataru, Sakurada, Yoichi, Sugiyama, Atsushi, Yoneyama, Seigo, Matsubara, Mio, Fukuda, Yoshiko, Kashiwagi, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961756/ https://www.ncbi.nlm.nih.gov/pubmed/33807964 http://dx.doi.org/10.3390/jcm10051098

Ejemplares similares

Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration
por: Shijo, Taiyo, et al.
Publicado: (2020)

Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2020)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
por: Kikushima, Wataru, et al.
Publicado: (2023)

Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degeneration
por: Fukuda, Yoshiko, et al.
Publicado: (2019)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Wataru, Kikushima, et al.
Publicado: (2020)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2020)

Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Yoneyama, Seigo, et al.
Publicado: (2020)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2021)

Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration
por: Kikushima, Wataru, et al.
Publicado: (2017)

Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2017)

Characteristics of intermediate age-related macular degeneration with hyperreflective foci
por: Kikushima, Wataru, et al.
Publicado: (2022)

Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results
por: Matsubara, Mio, et al.
Publicado: (2020)

Distinct characteristics of central serous chorioretinopathy according to gender
por: Yoneyama, Seigo, et al.
Publicado: (2022)

Incidence and risk of advanced age-related macular degeneration in eyes with drusenoid pigment epithelial detachment
por: Shijo, Taiyo, et al.
Publicado: (2022)

Prevalence and Genetic Characteristics of Geographic Atrophy among Elderly Japanese with Age-Related Macular Degeneration
por: Sakurada, Yoichi, et al.
Publicado: (2016)

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study
por: Sakamoto, Shinichi, et al.
Publicado: (2018)

Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline
por: Minami, Sakiko, et al.
Publicado: (2018)

Characteristics of Grape Shelf Eye Injuries at Vineyards in Japan
por: Kikushima, Wataru, et al.
Publicado: (2022)

The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation
por: Shigemoto, Yumi, et al.
Publicado: (2021)

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study
por: Rowe, Lucas W., et al.
Publicado: (2023)

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in a COVID-19 patient: A case report
por: Kogure, Chio, et al.
Publicado: (2021)

Comparison of the 1-Year Visual and Anatomical Outcomes between Subthreshold Red (670 nm) and Yellow (577 nm) Micro-Pulse Laser Treatment for Diabetic Macular Edema
por: Kikushima, Wataru, et al.
Publicado: (2021)

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity
por: Monés, Jordi, et al.
Publicado: (2012)

Drusenoid Pigment Epithelial Detachment: Genetic and Clinical Characteristics
por: Shijo, Taiyo, et al.
Publicado: (2021)

Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity
por: Chang, Young Suk, et al.
Publicado: (2014)

Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year
por: Singh, Sumit Randhir, et al.
Publicado: (2020)

One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity
por: Kwon, Ji Min, et al.
Publicado: (2021)

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO)
por: Cornish, E. E., et al.
Publicado: (2023)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike, Naoko, et al.
Publicado: (2019)

Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
por: Tatsumi, Tomoaki, et al.
Publicado: (2022)

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2017)

Mid-Term Results of Ab Interno Trabeculectomy among Japanese Glaucoma Patients
por: Kitamura, Kazuyoshi, et al.
Publicado: (2023)

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
por: Miyakubo, Tomoko, et al.
Publicado: (2023)

Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy with good baseline visual acuity
por: Hayashida, Mayuka, et al.
Publicado: (2020)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05
por: Koch, Raphael, et al.
Publicado: (2015)

Visual acuity loss associated with excessive “dry macula” in exudative age-related macular degeneration
por: Takahashi, Hidenori, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_phpj3hvsf68ulb23h4on8do26j